The gut microbiota drives aging-related erythropoiesis impairment via phenylacetic acid–induced histone phenylacetylation
- 22 October 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 148 (17) , 2176-2194
Abstract
Anemia, the most prevalent hematologic disorder in older adults, imposes a significant burden of cardiovascular events, cognitive decline, and mortality. However, the mechanisms underlying aging-related anemia, especially epigenetic dysregulation in hematopoietic stem and progenitor cells (HSPCs), remain incompletely understood. Although the gut microbiota is critical for hematopoiesis, its specific contribution to aging-related erythropoiesis impairment remains unclear. Here, we reveal that aging markedly activates phenylalanine metabolism and elevates plasma phenylacetic acid (PAA) levels in both humans and mice. We identify Odoribacter splanchnicus as a key gut symbiont whose abundance is significantly increased in aged mice and which directly drives PAA production from phenylalanine via the 2-oxoacid:ferredoxin oxidoreductase superfamily encoded by porA, nifJ, and iorA/iorB. Rifaximin treatment selectively reduces Osplanchnicus and plasma PAA, thereby alleviating aging-related anemia. Mechanistically, PAA promotes a novel posttranslational modification termed histone lysine phenylacetylation (Kpa) through the acetyltransferase histone acetyltransferase binding to origin recognition complex 1 (HBO1). Elevated histone Kpa increases chromatin accessibility at the GATA2 promoter, disrupts the GATA switch, and blocks erythroid differentiation of HSPCs. In vivo, supplementation with sodium phenylacetate exacerbates anemia in microbiota-depleted mice, whereas the HBO1 inhibitor WM-3835 restores erythropoiesis by reversing histone Kpa and normalizing the GATA switch. Furthermore, dietary phenylalanine restriction lowers circulating PAA and effectively ameliorates aging-related anemia in both naturally aged mice and Osplanchnicus–colonized mice. These findings provide, to our knowledge, the first evidence that gut microbiota–derived PAA plays a critical role in the development of aging-related erythropoiesis impairment and offer multiple translatable strategies for treating this condition.Keywords
This publication has 95 references indexed in Scilit:
- Rifaximin’s therapeutic spectrum: approved indications and experimental insights into emerging usesPharmacological Reports, 2026
- Faecalibaculum rodentium Alleviates Ionizing Radiation‐Induced Damage in Mice by Improving Intestinal Integrity and Hematopoiesis via Its Metabolite ButyrateAdvanced Science, 2025
- Gut microbiota‐derived butyric acid regulates calcific aortic valve disease pathogenesis by modulating GAPDH lactylation and butyrylationiMeta, 2025
- BRD8 Guards the Pluripotent State by Sensing and Maintaining Histone AcetylationAdvanced Science, 2024
- Identification of Histone Lysine Acetoacetylation as a Dynamic Post‐Translational Modification Regulated by HBO1Advanced Science, 2023
- Pleiotropic activities of succinate: The interplay between gut microbiota and cardiovascular diseasesiMeta, 2023
- Characteristics of fecal microbiota in non-alcoholic fatty liver disease patientsScience China Life Sciences, 2018
- Major phenylpropanoid‐derived metabolites in the human gut can arise from microbial fermentation of proteinMolecular Nutrition & Food Research, 2013
- Hemoglobin decline, function, and mortality in the elderly: The cardiovascular health studyAmerican Journal of Hematology, 2012
- Formation of Phenolic and Indolic Compounds by Anaerobic Bacteria in the Human Large IntestineMicrobial Ecology, 1997